Kane Biotech Inc.
KNBIF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -69.6% | -93.2% | 227.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | -60.3% | -162.6% | 10.3% | -69.3% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $0 | $0 | $1 | $0 |
| SG&A Expenses | $0 | $0 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $0 | $1 | $1 |
| Operating Income | -$1 | -$0 | -$1 | -$1 |
| % Margin | -6,394.1% | -983.9% | -281.5% | -811% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$0 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | -$1 |
| Net Income | -$1 | -$0 | -$1 | -$1 |
| % Margin | -7,146.1% | -1,244.9% | -295.4% | -860.4% |
| EPS | -0.004 | -0.002 | -0.008 | -0.008 |
| % Growth | -71.4% | 74.1% | -6.6% | – |
| EPS Diluted | -0.004 | -0.002 | -0.008 | -0.008 |
| Weighted Avg Shares Out | 167 | 163 | 150 | 142 |
| Weighted Avg Shares Out Dil | 167 | 181 | 150 | 138 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$1 | -$1 |
| % Margin | -5,874.3% | -705.3% | -269.6% | -760.3% |